Physician profile
Stuart B Pink
NPI 1700889847
$1,880.12
in general payments reported to CMS, 2019-2025
12 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $157 · 2021: $243 · 2022: $266 · 2023: $530 · 2024: $423 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $563.40 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Janssen Pharmaceuticals, INC | $321.09 | 2019-2024 | Xarelto |
| Cashflow Solutions, LLC | $183.99 | 2022-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Medtronic, INC. | $174.98 | 2021-2025 | Venaseal |
| Boston Scientific Corporation | $147.91 | 2023-2025 | Varithena Administration Pack |
| Integra Lifesciences Corporation | $139.10 | 2022-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Pfizer INC. | $108.50 | 2019-2022 | |
| Medtronic Vascular, INC. | $104.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.05 | 2023-2024 | Eliquis, Camzyos |
| Biocompatibles, INC. | $32.91 | 2019 | |
| Bard Peripheral Vascular, INC. | $27.94 | 2023 | Venclose Maven Catheter |
| Angiodynamics, INC. | $23.92 | 2023 | Venacure 1470 Pro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Pink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.